This is the key for me “…our strategy of bringing 67Cu-SAR-bisPSMA to earlier lines of prostate cancer therapy with the recent protocol amendment, given the exciting data in pre-chemotherapy participants.”
Earlier stage patients, pre-chemo. They will respond better to our therapy but also they don’t have to suffer chemo when they can try this safe option first; if this doesn’t work then chemo can be the next line of treatment. This also increases the TAM.
Safety was the focus of this phase of the trial and that endpoint has been met. People wanting big headline on efficacy would be disappointed.
One has to remember that patient’s bodies respond very subjectively to drugs- some responded at 4 and 8 GBqs but some are also slow to respond at 12Gbq. Their prior rounds of treatments would have a great impact on it.
That’s how I understand it. No advice.
I am still awaiting update on CLARIFY.
CU6 Price at posting:
$3.07 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)